Yüklüyor......
Pathogen Acquisition in Patients with Cystic Fibrosis Receiving Ivacaftor or Lumacaftor/Ivacaftor
BACKGROUND: The CFTR modulators ivacaftor and lumacaftor/ivacaftor improve the status of existing infections in patients with cystic fibrosis (CF). It is unknown how well these drugs protect patients against incident infections. We hypothesized that CFTR modulator treatment would decrease new infect...
Kaydedildi:
| Yayımlandı: | Pediatr Pulmonol |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6641998/ https://ncbi.nlm.nih.gov/pubmed/31012285 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ppul.24341 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|